Clinical Trials Logo

Filter by:
NCT ID: NCT03797612 Withdrawn - Pain, Postoperative Clinical Trials

Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS Scores

Start date: January 2021
Phase: Phase 2
Study type: Interventional

This is a multi-center, Phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of brivoligide injection administered intrathecally before surgery in patients with a Pain Catastrophizing Scale (PCS) score ≥16 undergoing primary unilateral total knee arthroplasty.

NCT ID: NCT03797443 Withdrawn - Clinical trials for Metastatic Pancreatic Cancer

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Start date: January 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to see if a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer. Vitamin C is a nutrient found in food and dietary supplements. It protects cells and also plays a key role in making collagen (which provides strength and structure to skin, bones, tissues and tendons). High-dose vitamin C may be given by intravenous (IV) infusion (through a vein into the bloodstream) or orally (taken by mouth). When taken by intravenous infusion, vitamin C can reach much higher levels in the blood than when the same amount is taken by mouth. Some human studies of high-dose IV vitamin C in patients with cancer have shown improved quality of life, as well as improvements in physical, mental, and emotional functions, symptoms of fatigue, nausea and vomiting, pain, and appetite loss. Intravenous high-dose ascorbic acid has caused very few side effects in clinical trials.

NCT ID: NCT03797287 Withdrawn - Shoulder Pain Clinical Trials

Arthroscopic Transosseous vs. Anchored Rotator Cuff Repair

Start date: February 1, 2020
Phase: N/A
Study type: Interventional

This study will compare arthroscopic transosseous versus anchored rotator cuff repairs in terms of clinical outcomes, rotator cuff integrity, and cost-effectiveness. With the collection of patient-reported outcomes the health of patients undergoing each rotator cuff repair technique will be assessed. The aims of this study will be achieved through a clinical randomized controlled trial and a cost-effectiveness analysis.

NCT ID: NCT03796507 Withdrawn - Glioma of Brain Clinical Trials

Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation

Start date: September 1, 2021
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to investigate the feasibility of a possible treatment regimen that could be used to delay tumor progression in patients with glioblastoma. The study is being conducted in patients who qualify for inpatient rehabilitation, as this population is particularly vulnerable to delays in initiation of chemoradiation and further tumor growth in the period between surgical resection and the start of treatment.

NCT ID: NCT03794973 Withdrawn - Clinical trials for Diabetes Mellitus, Type 1

Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)

DAWN
Start date: December 14, 2019
Phase: Phase 2
Study type: Interventional

The study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial in subjects with new onset T1D.

NCT ID: NCT03794570 Withdrawn - ACL Injury Clinical Trials

BFR Therapy After ACL Reconstruction

BFR
Start date: December 18, 2018
Phase: N/A
Study type: Interventional

This study is a prospective, double-blinded, randomized control trial examining the effect of blood flow restriction (BFR) therapy on reducing post-operative quadriceps atrophy in patients undergoing anterior cruciate ligament reconstruction (ACLR). Following ACLR, patients will undergo a rehabilitation protocol either w/ BFR therapy or sham BFR therapy.

NCT ID: NCT03794297 Withdrawn - Clinical trials for Erdheim-Chester Disease

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

Start date: January 4, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well dabrafenib and trametinib work in treating patients with Erdheim Chester disease that have BRAF V600 gene mutations. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03792295 Withdrawn - Pain Clinical Trials

Multimodal Pain Therapy After Hernia Repair

Start date: July 1, 2021
Phase: Phase 2
Study type: Interventional

Investigating the effect of multimodal pain treatment after hernia repair

NCT ID: NCT03791541 Withdrawn - Clinical trials for The Focus is to Test a Survey Predicting Readmissions

A Study Evaluating the Use of Potential Predictors of Readmission in Hospitalized Medicine Patients

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

The primary objective of this study is the development and implementation of a survey administered to hospitalized patients on Internal Medicine that can be used in conjunction with previously validated predictive indices to identify patients at risk for readmission. The survey consists of previously validated as well as investigator developed survey instruments that will assess the following: health literacy, numeracy, medication adherence, self-efficacy, and tolerance. The predictive indices are the LACE, Charlson Comorbidity Index (included in LACE), and the Comorbidity Polypharmacy Score (CPS) which have been previously validated for risk of readmissions. The survey consists of both closed and open ended questions. A part of the survey will be administered by the study personnel while the rest is a questionnaire-based survey that will be completed by the subjects. Study personnel will be with the subjects in an open dialogue while subjects are completing the survey to answer any questions and identify questions that may be confusing or bias subjects. Approximately 30 days after hospital discharge, patients will be contacted via telephone to ask how many admissions and/or Emergency Department (ED) visits they have had since discharge. A correlation analysis will be done of the different aspects of the survey to determine whether there are redundancies. A regression analysis will be done to determine the predictive ability of the survey combined with predictive indices for readmission.

NCT ID: NCT03789773 Withdrawn - Clinical trials for Unspecified Adult Solid Tumor

Holographic Mm-Wave Imaging in Patients Undergoing Radiation Therapy

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

This trial studies the quality of holographic mm-wave imaging in patients undergoing radiation therapy. Holographic mm-wave imaging is a common type of imaging used in airport body scanners that may be helpful in improving the efficiency and positioning of radiation oncology patients and their overall experience.